SCHEMBL26101618

SCHEMBL26101618

CNc1cc(Nc2cccn(-c3cccc(C(=O)OC)c3)c2=O)nn2c(C(=O)N[C@@H]3C[C@@H]3F)cnc12

nearest known ligand 0.71

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 20/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30392674 1.00 TYK2 (0.71) TYK2
SCHEMBL26099284 0.93 TYK2 (0.73) TYK2
SCHEMBL30393122 0.93 TYK2 (0.73) TYK2
SCHEMBL26101358 0.89 TYK2 (0.79) TYK2
SCHEMBL26101540 0.89 TYK2 (0.82) TYK2
SCHEMBL31218701 0.86 TYK2 (0.74) TYK2
SCHEMBL30392864 0.84 TYK2 (0.52) TYK2
SCHEMBL26101032 0.84 TYK2 (0.52) TYK2
SCHEMBL16812464 0.83 TYK2 (0.84) TYK2
SCHEMBL18143587 0.83 TYK2 (0.86) TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 — — US disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A TYK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback